ERYP - ERYTECH Pharma S.A.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.14
+0.55 (+8.35%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close6.59
Open8.02
Bid6.78 x 1100
Ask7.76 x 1000
Day's Range7.14 - 8.73
52 Week Range3.50 - 12.00
Volume3,240
Avg. Volume1,987
Market Cap134.505M
Beta (5Y Monthly)1.50
PE Ratio (TTM)N/A
EPS (TTM)-2.79
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.47
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Monthly information related to total number of voting rights and shares composing the share capital – June 30, 2020

      LYON, France, July 10, 2020 -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext.

    • GlobeNewswire

      ERYTECH Reports Voting Results from its Annual General Meeting Held on June 26, 2020

      LYON, France and CAMBRIDGE, Mass., June 26, 2020 -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP) announced that its 2020 Annual General Meeting was held in Lyon on Friday,.

    • The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy
      Benzinga

      The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy

      The following is a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24) * ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) * BioXcel Therapeutics Inc (NASDAQ: BTAI) * Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI) (announced new clinical program focused on the development of NurOwn as a treatment for Alzheimer's disease) * Burning Rock Biotech Ltd (NASDAQ: BNR) (went public June 12) * Cardiff Oncology Inc (NASDAQ: CRDF) * ESSA Pharma Inc (NASDAQ: EPIX) * Five Prime Therapeutics Inc (NASDAQ: FPRX) * Horizon Therapeutics PLC (NASDAQ: HZNP) * IGM Biosciences Inc (NASDAQ: IGMS) * Inovio Pharmaceuticals Inc (NASDAQ: INO) * Kamada Ltd. (NASDAQ: KMDA) * Novavax, Inc. (NASDAQ: NVAX) * Passage Bio Inc (NASDAQ: PASG) * Pliant Therapeutics Inc (NASDAQ: PLRX) * Translate Bio Inc (NASDAQ: TBIO) * Twist Bioscience Corp (NASDAQ: TWST)Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 24) * Genetron Holdings Ltd - ADR (NASDAQ: GTH) (went public Friday) * Vaccinex Inc (NASDAQ: VCNX)Stocks In Focus Merck's Keytruda Approved For Skin Cancer Merck & Co., Inc. (NYSE: MRK) said the FDA as approved Keytruda, its anti-PD-1 therapy, as monotherapy for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma that is not curable by surgery or radiation.In pre-market trading, Merck shares were down 0.65% to $75.38.UniQure Out-Licenses Investigational Late-Stage Hemophilia B Gene Therapy For Up To $2.05B Gene therapy company Uniqure NV (NASDAQ: QURE) said it has entered into a licensing agreement with CSL Behring, providing the latter with exclusive global rights to etranacogene dezaparvovec, uniQure's investigational gene therapy for patients with hemophilia B.The agreement provides for uniQure receiving a $450 million upfront cash payment and potentially up to $1.6 billion in payments based on regulatory and commercial milestones. The company is also eligible to receive tiered double-digit royalties in a range of up to a low-20s percentage of net product sales arising from the collaboration.UniQure said the proposed transaction will provide significant financial resources to advance and expand its pipeline of gene therapy candidates, anchored by AMT-130 in Huntington's disease, and to invest further in its leading gene therapy manufacturing and technology platform to support pipeline growth.The stock was down 16.39% at $52.60 premarket Thursday.La Jolla Agrees To Buy Tetraphase After protracted three-way wrangling, Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) clinched a definitive merger agreement to be bought by La Jolla Pharmaceutical Company (NASDAQ: LJPC) for $43 million in upfront cash, plus potential future cash payments of up to $16 million pursuant to contingent value rights.Melinta, which had earlier agreed to buy Tetraphase, terminated the agreement, and was paid $1.15 million as a break-up fee.In after-hours trading, Tetraphase shares declined 1.85% to $2.65, while La Jolla gained 2.08% to $4.90.See also: The Week Ahead In Biotech: Karyopharm, Zogenix, Heron, Chiasma On The Radar Ahead Of FDA Decisions Theravance Doses First Patient In Phase 2 COVID-19 Study Theravance Biopharma Inc (NASDAQ: TBPH) said the first COVID-19 patient has been dosed in a Phase 2 study of TD-0903, its lung-selective, nebulized Janus kinase inhibitor in development for the potential treatment of hospitalized patients with acute lung Injury caused by COVID-19.Offerings HUTCHISON CHINA/S ADR (NASDAQ: HCM) announced that it has entered into a definitive agreement for the sale of $100 million of shares at $25 per ADS through a private placement to private equity firm General Atlantic.This fundraise could increase to $200 million through a warrant granted with a term of 18 months for a further $100 million in Chi-Med shares exercisable at a price per share equivalent to $30 per ADS, the company said. Erytech Pharma SA (NASDAQ: ERYP) announced the signing of an agreement with the Luxembourg-based European High Growth Opportunities Securitization Fund for issuing convertible notes valued up to a maximum of 60 million euros ($67.2 million) in the event of conversion of all the notes, subject to the regulatory limit of 20% dilution.View more earnings on IBBErytech said the financing line aims at improving its financial strength and extending its cash horizon for the next key development milestones.Xeris Pharmaceuticals Inc (NASDAQ: XERS) said it has commenced concurrent underwritten public offerings of $20 million in shares of its common stock and $60 million in aggregate principal amount of convertible senior notes due 2025. The company expects the net proceeds to finance the commercialization of Gvoke and repay a $20 million loan, among other things.The stock was down 19.96% at $4.25 premarket. Evelo Biosciences Inc (NASDAQ: EVLO) priced its underwritten public offering of 12 million shares of its common stock at $3.75 per share for gross proceeds of $45 million. All of the shares in the offering are to be sold by the company. The offering is expected to close on or about June 29.The stock was down 8.98% at $3.65 premarket. Nantkwest Inc (NASDAQ: NK) priced its underwritten public offering of 7.41 million shares, with 3.7 million shares to be priced at $9.50 per share and the remaining 3.7 million shares at $12.12 per share to its CEO and principal stockholder Dr. Patrick Soon-Shiong. The aggregate gross proceeds from the offering are expected to be approximately $80.1 million.In after-hours trading, the stock shed 9.39% to $11.Translate Bio said it has commenced an underwritten public offering of $125 million of its common stock. In addition, Shire, a subsidiary of Takeda Pharmaceutical Co Ltd (NYSE: TAK), is offering 6.825 million of its common stock in the offering. The company clarified that it will not receive any proceeds from the shares sold by Shire.Translate Bio shares were down 6.64% at $24.89 premarket Thursday.Magenta Therapeutics Inc (NASDAQ: MGTA) priced its underwritten public offering of 7.5 million shares of its common stock at $8 per share for gross proceeds of $60 million. All the shares earmarked for the offering are sold by the company.On The Radar PDUFA Dates The FDA is set to rule on Zogenix, Inc.'s (NASDAQ: ZGNX) NDA for Fintepla as a potential treatment candidate for seizures associated with Dravet syndrome.Earnings * Aethlon Medical, Inc. (NASDAQ: AEMD) (after the close)Related Link: Evoke Gets FDA Nod For Gimoti, A Nasally-Administered Gastroparesis Drug See more from Benzinga * The Daily Biotech Pulse: MediciNova On Track For European Patent Win, Partial Clinical Hold Lifted For Innate Pharma, Tela Bio Details Coronavirus Impact * The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    • GlobeNewswire

      ERYTECH extends its cash horizon by implementing a convertible bond financing

      The notes come with share warrants representing 10% of the nominal amount of the issued notes whose exercise price will reflect a 20% premium over the lowest volume-weighted average daily price of the share over the reference period preceding the issue of the first tranche. The issuance of the 1,200 note warrants (bons d'émission) (the "Notes Warrants" or "BEOCABSA") and of the tranches of convertible bonds (the "Notes") with warrants attached (the "Warrants" and together with the Notes, the "OCABSA") will be made pursuant to the 25th resolution of the extraordinary general shareholder's meeting held on June 21, 2019 (the "Shareholder's Meeting").

    • GlobeNewswire

      Monthly information related to total number of voting rights and shares composing the share capital – May 30, 2020

      LYON, France, June 09, 2020 -- Article 223-16 of general regulation of French Autorité des Marchés FinanciersLyon – France Listing markets: Euronext Paris from Euronext.

    • GlobeNewswire

      ERYTECH Provides Update on Phase 2 Investigator Sponsored Trial of Eryaspase in Second-Line Acute Lymphoblastic Leukemia

      ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided an update on the ongoing Phase 2 trial, sponsored by the Nordic Society of Paediatric Haematology and Oncology (NOPHO) of eryaspase in second-line acute lymphoblastic leukemia (ALL) patients. The NOR-GRASPALL-2016 trial is evaluating the safety and activity of eryaspase in primarily pediatric acute lymphoblastic leukemia (ALL) patients who developed hypersensitivity reactions to pegylated asparaginase.

    • GlobeNewswire

      ERYTECH to Participate Fireside Chat at Jefferies Virtual Healthcare Conference

      ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Gil BEYEN, Chief Executive Officer, will be participating in a fireside chat at the Jefferies Virtual Healthcare Conference on June 4, 2020, at 08:30 am ET. ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs.

    • Erytech Pharma SA Sponsored ADR (ERYP) Upgraded to Buy: Here's What You Should Know
      Zacks

      Erytech Pharma SA Sponsored ADR (ERYP) Upgraded to Buy: Here's What You Should Know

      Erytech Pharma SA Sponsored ADR (ERYP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

    • GlobeNewswire

      ERYTECH Announces Poster Presentations at ASCO 2020 Annual Meeting

      ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announces the presentation of two posters at the American Society of Clinical Oncology (ASCO) 2020 Virtual Meeting. TRYbeCA-1 is a randomized, controlled Phase 3 clinical trial evaluating eryaspase in second-line metastatic pancreatic cancer. An interim efficacy analysis is planned for when approximately two- thirds of events have occurred.

    • GlobeNewswire

      Erytech’s Combined Shareholders’ Meeting

      Meeting held in closed session on June 26, 2020 Live webcast of the Shareholders’ Meeting Availability of the preparatory documents for the Shareholders’ Meeting LYON,.

    • GlobeNewswire

      Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2020

      LYON, France, May 07, 2020 -- Article 223-16 of general regulation of French Autorité des Marchés FinanciersLyon – France Listing markets: Euronext Paris from Euronext.

    • GlobeNewswire

      ERYTECH Provides Business Update and Reports Cash Balance at End of Q1 2020

      ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business and financial update. “Our focus during the past several weeks of the COVID-19 pandemic has been to continue our clinical operations and preserving study integrity while ensuring the health of our employees, the patients and the medical professionals involved in our clinical programs,” said Gil Beyen, CEO of ERYTECH Pharma. With more than 75% of patients enrolled in the TRYbeCA-1 Phase 3 trial and based on the event rate observed thus far, we expect to report the results of the interim superiority analysis around year-end of 2020 and the final result in the second half of 2021.

    • GlobeNewswire

      ERYTECH engages in collaborative partnership with EU Horizon 2020 EVIDENCE consortium

      ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced it will be part of EVIDENCE, a public-private consortium supported by the European Union in the framework of the EU Horizon 2020 program. The EVIDENCE consortium, consisting of leading experts in the field of red blood cell research, will explore how red blood cells are influenced by their extra-cellular environment. The EVIDENCE consortium will investigate the behavior of red blood cells under physiological flow conditions, i.e.

    • Is ERYTECH Pharma (EPA:ERYP) Using Debt In A Risky Way?
      Simply Wall St.

      Is ERYTECH Pharma (EPA:ERYP) Using Debt In A Risky Way?

      Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

    • GlobeNewswire

      ERYTECH to Host on May 7, 2020 First Quarter Conference Call and Business Update

      LYON, France, April 30, 2020 -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by.

    • GlobeNewswire

      ERYTECH Granted U.S. FDA Fast Track Designation for eryaspase in Second-Line Pancreatic Cancer

      Fast Track designation for eryaspase underscores the urgent need for potential new treatment options for patients with second line metastatic pancreatic cancer LYON, France.

    • GlobeNewswire

      ERYTECH Provides Update on the TRYbeCA-1 Phase 3 Clinical Trial of Eryaspase in Second Line Pancreatic Cancer

      ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing red blood cell-based cancer therapeutics, today  provided an update on the pivotal Phase 3 clinical trial for advanced metastatic pancreatic cancer (TRYbeCA-1), which is evaluating the efficacy and safety of ERYTECH’s lead product candidate eryaspase in combination with chemotherapy as second-line therapy. “We are pleased that the TRYbeCA-1 trial has continued to progress well despite the challenges caused by the COVID-19 global pandemic,” said Gil Beyen, CEO of ERYTECH.

    • GlobeNewswire

      Monthly information related to total number of voting rights and shares composing the share capital – March 31, 2020

      LYON, France, April 06, 2020 -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext.

    • GlobeNewswire

      ERYTECH Announces Filing of 2019 Universal Registration Document and 2019 Annual Report on Form 20-F

      ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced that it had filed its 2019 Universal Registration Document for the year ended December 31, 2019, including the management report and the annual financial report with the “Autorité des Marchés Financiers (AMF)” and its Annual Report on Form 20-F for the year ended December 31, 2019 with the U.S. Securities and Exchange Commission (SEC).

    • GlobeNewswire

      ERYTECH Provides Business Update and Reports Financial Results for the Full Year 2019

      ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business update and reported its financial results for the fourth quarter and year ended December 31, 2019. “2019 has been a year of tremendous execution towards realizing our vision of helping cancer patients to live longer and better,” said Gil Beyen, CEO of ERYTECH.

    • GlobeNewswire

      ERYTECH Announces the Appointment of Dr. Melanie Rolli to its Board of Directors

      ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the appointment of Melanie Rolli, M.D.,  to its Board of Directors and the intention to propose the ratification of her appointment at ERYTECH’s next General Meeting of Shareholders. Dr. Rolli has more than 15 years of experience in the global biopharmaceutical and biotechnology industry, including in both Europe and the United States. Dr. Rolli’s appointment follows the resignation of Allene Diaz, who resigned from the Board effective September 30, 2019.

    • GlobeNewswire

      ERYTECH to Host Fourth Quarter and Full Year 2019 Conference Call and Business Update

      LYON, France, March 12, 2020 -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by.

    • GlobeNewswire

      Monthly information related to total number of voting rights and shares composing the share capital – February 29, 2020

      LYON, France, March 06, 2020 -- Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market.

    • GlobeNewswire

      ERYTECH to Present at Cowen and Company 40th Annual Health Care Conference

      LYON, France and CAMBRIDGE, Mass., Feb. 26, 2020 -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies.

    • GlobeNewswire

      ERYTECH Enters Into Strategic Supply Partnership with the German Red Cross Blood Donor Service

      ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that it has entered into a strategic partnership with the German Red Cross Blood Donor Service Baden-Württemberg-Hessen (GRCBDS) to complement the existing alliance with the French Blood bank (EFS) for the supply of donor red blood cells to manufacture its product candidates, including eryaspase, in Europe. The GRCBDS is one of the world’s largest blood and transfusion services, ensuring safe and adequate supply of blood products for approximately 30 million Germans (more than one-third of the German population).